Regeneron Says Samsung Eye Med Biosimilar Will Infringe IP
Regeneron has struck back against a bid by Samsung Bioepis to revoke two of its eye medicine patents, telling a London court that its rival's planned biosimilar will result in infringement....To view the full article, register now.
Already a subscriber? Click here to view full article